Variation in patient profiles and outcomes in US and Non-US subgroups of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) PHOENIX trial

Circulation: Cardiovascular Interventions

Volumn 9, Issue 6, 2016, Pages

  Vaduganathan, Muthiah ^a   Harrington, Robert A ^b   Stone, Gregg W ^c   Steg, Ph Gabriel ^d,e   Gibson, C Michael ^f   Hamm, Christian W ^g   Price, Matthew J ^h   Prats, Jayne ⁱ   Deliargyris, Efthymios N ⁱ   Mahaffey, Kenneth W ^b   White, Harvey D ^j   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g Kerckhoff Heart and Thorax Center   (Germany)

^h SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

ⁱ Medicines Company   (United States)

^j Green Lane Cardiovascular Service ^*  (New Zealand)

more..

Author keywords

antiplatelet therapy; clinical trial; international comparison; percutaneous coronary intervention; variation

Indexed keywords

CANGRELOR; CLOPIDOGREL; HIRULOG; PLACEBO; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR PROCEDURE; CARDIOVASCULAR RISK; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE; UNITED STATES; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; BRAZIL; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFECTS; EUROPE; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; NEW ZEALAND; ODDS RATIO; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; THAILAND; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE MONOPHOSPHATE; AGED; BRAZIL; CHI-SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW ZEALAND; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RISK FACTORS; THAILAND; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84975686967     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.116.003612     Document Type: Article

References (19)

1. FDA approves new antiplatelet drug used during heart procedure [press release]. Available at: http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm452172.htm. Accessed December 21, 2015
2. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013; 368: 1303-1313. doi: 10.1056/NEJMoa1300815
3. Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63: 619-629. doi: 10.1016/j.jacc.2013.10.022
4. O'Shea JC, Calif RM. Inter-regional differences in acute coronary syndrome trials. Eur Heart J. 2000; 21: 1397-1399. doi: 10.1053/euhj. 2000.2121
5. Bhatt DL, Cavender MA. Are all clinical trial sites created equal' J Am Coll Cardiol. 2013; 61: 580-581. doi: 10.1016/j.jacc.2012.10.024
6. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124: 544-554. doi: 10.1161/CIRCULATIONAHA.111.047498
7. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, Merkely B, Baracioli L, Schersten F, Seabro-Gomes R, Braunwald E, Wiviott SD; TRITON-TIMI 38 Investigators. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012; 155: 424-429. doi: 10.1016/j.ijcard.2010.10.040
8. Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PHOENIX trial. Am Heart J. 2012; 163: 768-776.e2. doi: 10.1016/j. ahj.2012.02.018
9. CHAMPION PHOENIX-protocol & SAP supplement. Available at: http://www.nejm.org/doi/suppl/10.1056/NEJMoa1300815/suppl-file/nejmoa1300815-protocol.pdf. Assessed December 21, 2015
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115: 2344-2351. doi: 10.1161/CIRCULATIONAHA. 106.685313
11. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007; 116: 2634-2653. doi: 10.1161/CIRULATIONAHA.107.187397
12. Bernardez-Pereira S, Lopes RD, Carrion MJ, Santucci EV, Soares RM, de Oliveira Abreu M, Laranjeira LN, Ikeoka DT, Zazula AD, Moreira FR, Cavalcanti AB, Mesquita ET, Peterson ED, Califf RM, Berwanger O. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. Am Heart J. 2014; 168: 213-219.e1
13. Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015; 313: 174-189. doi: 10.1001/jama.2014.15939
14. Getz KA. Global Clinical Trials Activity in the Details. Applied Clinical Trials. 2007
15. Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M; EVEREST Investigators. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013; 61: 571-579. doi: 10.1016/j.jacc.2012.10.025
16. Tobbia P, Brodie BR, Stuckey T, McLaurin BT, Cox DA, Fahy M, Xu K, Mehran R, Stone GW. Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial. Catheter Cardiovasc Interv. 2013; 82: E365-E374. doi: 10.1002/ccd.24587
17. Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, Kellett MA, Stuckey T, Fahy M, Mehran R, Stone GW. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention. 2013; 8: 1134-1142. doi: 10.4244/EIJV8I10A176
18. Franchi F, Rollini F, Muñiz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013; 11: 1279-1291. doi: 10.1586/14779072.2013.837701
19. Pocock S, Calvo G, Marrugat J, Prasad K, Tavazzi L, Wallentin L, Zannad F, Alonso Garcia A. International differences in treatment effect: do they really exist and why? Eur Heart J. 2013; 34: 1846-1852. doi: 10.1093/eurheartj/eht071